Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment

Documenti analoghi

• Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model
  di: Zimin Zhang, et al.
  Pubblicazione: (2025)
• Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
  di: Shota Yanagida, et al.
  Pubblicazione: (2025)
• Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis
  di: Rasmus Hansen Henninger, et al.
  Pubblicazione: (2026)
• Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital
  di: Gayathri Baburaj, et al.
  Pubblicazione: (2026)
• AI ‐Driven Variant Annotation for Precision Oncology in Breast Cancer
  di: Kriti Shukla, et al.
  Pubblicazione: (2025)